Oral Mucositis
Conditions
Keywords
Radiation, mucositis, head and neck carcinoma, oral rinse, amlexanox, MuGard
Brief summary
The purpose of this study was to determine the effect of 0.5% amlexanox oral rinse compared to a vehicle control on mucositis-related ulceration and erythema (objective score)and on mucositis-related oral pain (subjective score). A secondary objective was to evaluate the safety of 0.5% amlexanox oral rinse by determining the frequency of treatment-emergent drug-related adverse events or clinical laboratory abnormalities.
Interventions
DRUGamlexanox
0.5% amlexanox oral rinse; use 5 ml every 2-3 hours during the awake hours of each day (a minimum of 6 times each day). The liquid was be swirled around the mouth then to be swallowed. Repeated daily until completion of radiation therapy: approximately 7-8 weeks.
DRUGVehicle rinse
use 5 ml of the vehicle rinse every 2-3 hours during the awake hours of each day (a minimum of 6 times each day). The liquid is be swirled around the mouth then swallowed.
Sponsors
Advanced Clinical Research Services, LLC
Access Pharmaceuticals, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient is 18 years of age or older; 2. Patient has a histologically documented diagnosis of cancer of the head and neck region; 3. Patient is about to receive a course of radiation therapy (with or without concomitant chemotherapy) with a planned dose of at least 60 Gy over 6-7 weeks, and with planned fields to involve at least 50% of the oral mucosa; This criterion was amended (Amendment 01 dated August 28, 2000) to read as follows: 3\. Amended: Patient is at a high risk of developing radiation-induced mucositis. For the purpose of this study, high-risk patients will be defined as: 1. patients about to receive a course of radiation therapy (with or without concomitant chemotherapy) with a planned dose of at least 60 Gy over 6-7 weeks, and 2. with planned fields to involve at least 40% of the oral and oropharyngeal mucosa visible by direct inspection; 4\. Patient has a Karnofsky Performance Scale (KPS) score of 60% or more; 5\. Patient is willing and able to cooperate with the protocol including rinsing of the oral cavity with the investigational or vehicle oral rinse 6 times per day. 6\. The patient or guardian is capable of providing informed consent. 7\. If female, the subject has undergone a urine pregnancy test with negative results, and has agreed to practice effective methods of contraception for the duration of the study.
Exclusion criteria
1. Patient has had previous radiation therapy to the oral mucosa; 2. Patient is about to receive hyperfractionated radiation therapy; 3. Patient has active oral H. simplex lesions, oral candidiasis, or oral mucositis due to other disease processes; 4. Patient has uncontrolled infection; 5. Patient has HIV, Hepatitis B (HBV) (as measured by HBs-Ag) or Hepatitis C (HCV) infection; 6. Patient has not recovered from oral toxicity attributable to prior treatment; 7. Patient has abnormal laboratory values that meet the following criteria: * Serum creatinine greater than 2 x upper limit of normal * Total bilirubin greater than 3 x upper limit of normal; * SGOT greater than 3 x upper limit of normal; * LDH greater than 3 x upper limit of normal; 8. Patient has known sensitivities to any of the study preparation ingredients; 9. Patient has participated in a clinical research study within the last 30 days prior to enrollment; 10. Patient is unable to communicate or cooperate with the investigator due to language problems, poor mental development, or other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of mucositis using the Oral Mucositis Assessment Score | 7 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Frequency of treatment-emergent, drug-related Serious Adverse Events | 7 weeks |
Countries
United States
Outcome results
None listed